China Sxt Pharmaceuticals Inc Stock Price, News & Analysis

China SXT Pharmaceuticals, Inc. (SXTC) announced a public offering of approximately 19.8 million ordinary shares, priced at $0.18 per share, aiming for gross proceeds of $3.5 million. An additional option allows underwriters to purchase 2.97 million shares, potentially raising proceeds to $4.1 million. The funds will support general corporate purposes and working capital. The offering's closing is anticipated on January 20, 2022, pending customary conditions. Aegis Capital Corp. is the sole book-running manager for this offering.

China SXT Pharmaceuticals (SXTC) announced plans for an underwritten public offering of its ordinary shares and prefunded warrants, aiming to raise approximately $3.4 million. The funds will be allocated for general corporate purposes, including working capital and business opportunities. The offering is contingent on market conditions, with an overallotment option for underwriters to purchase an additional 15% within 45 days post-closing. Aegis Capital Corp. serves as the sole book-running manager. Investors are advised to review the preliminary prospectus for further details.

China SXT Pharmaceuticals (NASDAQ: SXTC) announced the development of Kuihuapan and Zhudanfen, two new Advanced TCMP products, aimed at enhancing its market presence. The annual output is anticipated to reach 300,000 bottles, generating sales of approximately RMB 5 million by March 31, 2023. The company is also focusing on increasing production capacity for its Luxuejin product, expecting sales of over RMB 3 million for the fiscal year ending March 31, 2022. The development leverages Chinese Pharmacopoeia standards to improve clinical effectiveness while meeting rising market demand.

China SXT Pharmaceuticals, Inc. (SXTC) announced on December 14, 2021, that it received a notification from Nasdaq regarding its ordinary shares' minimum bid price, which has been below $1.00 for 30 consecutive business days. The notification does not impact the current listing but requires the Company to regain compliance by June 13, 2022. SXTC must achieve a closing bid price of at least $1 for 10 consecutive business days to comply. If compliance is not met, the Company may be eligible for an additional 180 days, potentially involving a reverse stock split.

On October 18, 2021, China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced it received a new Pharmaceutical Manufacturing Permit from the Jiangsu Province Medical Products Administration. This permit allows the company to expand its production to include lyophilization processing, a technique that enhances product stability and solubility. The company claims it will be the first in China to manufacture Directly-Oral TCMPs under this new permit. The lyophilization process is essential for their product Luxuejing, aimed at treating various health conditions.

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced a 1 for 4 reverse share split effective on February 19, 2021. Shareholders will receive one new share for every four shares they hold. Post-split, ordinary shares are expected to trade at about four times their previous price, but the company cautioned that this price may not be sustained. Approximately 62 million ordinary shares will reduce to about 15.5 million following the split. This action aims to manage share price and liquidity.

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) announced it received a 180-day extension from NASDAQ until March 8, 2021, to meet the minimum bid price requirement of $1.00 per share. The extension was granted as the company met other listing requirements, although it still needs to address the bid price issue. The company plans to potentially implement a reverse stock split if necessary. If compliance isn't achieved, delisting could occur, but the stock remains trading on NASDAQ for now. The company focuses on Traditional Chinese Medicine manufacturing and sales.